Ayble Health secured a $16 million oversubscribed series A funding round to accelerate its expansion into artificial intelligence-driven precision digestive and autoimmune healthcare.
Neon led the funding round, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx, Accomplice and several individual investors.
“I've been tracking the GI space closely for years, and what Ayble has built is different,” said Kimmy Scotti, Neon founding and managing partner, in a statement. “Having invested early in top digital health companies, I've seen what it takes to build a category-defining company in healthcare. Ayble has spent years building the clinical evidence before they scaled the business. That earns trust from the full ecosystem: health systems, payers, and most importantly, patients, and it’s what makes a durable market leader."
The company says it combines specialized clinical expertise with advanced technology.
Ayble Health plans to use the funding to advance its proprietary AI and clinician precision care model, as well as strengthen its data-driven personalization for patient engagement, enrollment and care. The company also plans to expand beyond its core GI focus into adjacent areas, beginning with autoimmune conditions.
Executives tout the company’s rapid growth over the past several years, including Amazon Health’s Benefits Connector selecting it as the first digital gastrointestinal (GI) solution. Ayble says it is currently in-network with most commercial health plans, covering more than 80 million patients through its various partnerships. Collaborations include Mayo Clinic, Cleveland Clinic, Priority Health, Castlight Health and others.
"I built Ayble because I'm an Inflammatory Bowel Disease patient," said Sam Jactel, Ayble Health founder and CEO, in a statement. “I've lived through the diagnostic delays, the care gaps, and the overall frustration of a system that isn't designed for patients who need ongoing, coordinated care.”
Jactel said many patients are also managing autoimmune conditions, adding that “too often, no one is treating the whole picture.”
“This funding lets us close that gap: deepening our AI precision care capabilities and extending our multidisciplinary model into autoimmune, so patients get one team built for how these conditions actually show up in their lives,” Jactel said. “The growth we’ve seen and the partnerships we’ve built with leading employers, payers and providers demonstrates the need for our work is massive.”
Ayble Health has raised more than $27 million to date, executives say.